Court of Auditors urges rollout of electronic vaccination records by 2028
Translated from French and summarized by DistantNews. Read the original for the full story.
At a glance
Newswire
Documents & data
New plan
- France’s Court of Auditors called for electronic vaccination records to be fully rolled out by 2028 and for all vaccinators to enter administered doses into the national health app.
- Only 35% of social security beneficiaries have activated Mon Espace Santé, and vaccination data appear for just 11% of those users, the court said.
- The court also questioned the value of newer, more expensive flu vaccines, saying some cost more than twice as much as standard products for at most modest additional effectiveness.
France’s Court of Auditors wants every person to have an up-to-date electronic vaccination record by 2028. Amélie de Montchalin, the court’s president, said the lack of such a record creates “a major obstacle to our individual protection.”
The electronic record is integrated into Mon Espace Santé, France’s digital health record, which users can access on a smartphone. But only 35% of social security beneficiaries have activated the application, according to the court. Among those users, vaccination information appears in only 11% of records.
The fact that we do not each have an up-to-date electronic vaccination record is a major obstacle to our individual protection.
The court said pharmacists, who administer flu vaccines, are currently the main health professionals entering vaccination data into Mon Espace Santé. The computer systems used by other vaccinators, including doctors, often do not allow patient records to be updated quickly and smoothly.
It is also a point of fragility in public health.
The report calls on all vaccinators to record administered vaccines in the system by 2028. It also wants every beneficiary to be able to recover their full vaccination history in the digital record by the same deadline. Montchalin said that many people do not know their vaccination status or whether they need booster shots. She also described the gap as a public health vulnerability because authorities do not know the population’s level of protection when an epidemic occurs.
The Court of Auditors also urged closer evaluation of costly new vaccines. It said some higher-dose or adjuvanted flu vaccines, including Sanofi’s Efluelda and CSL Seqirus’s Fluad, cost more than twice as much as conventional vaccines while offering, at best, modest additional effectiveness. The court said France’s health authority should use the same commission to set vaccine strategy, assess medical benefit and evaluate budgetary impact and cost-effectiveness.
Some higher-dose or adjuvanted flu vaccines cost more than twice as much as conventional vaccines, for additional effectiveness judged at best modest.
About this summary
Originally published by Le Figaro in French. Translated, summarized, and contextualized automatically by DistantNews, with a note on how the source frames the story. Not individually reviewed before publishing. How this works.
More Stories
From Our Blog
News in Translation: What Gets Lost, and How We Keep the Framing
Diaspora Media: How Communities Follow News From Home
Traveling Where the Press Is Not Free: How to Read the News There
The Digital Nomad's Guide to Local News
The Same Story, Different Countries: How Coverage Changes at the Border
